Injection site reactions are the most common side effect of Emgality. The most frequent injection site reaction is pain. But there are steps you can take to help prevent or reduce pain from Emgality ...

Leqvio (inclisiran) may cause injection site reactions, including bruising, pain, discoloration, itchiness, and a burning or prickling sensation at the injection site. In addition to injection site ...

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but ...

Despite injection-site reactions, teens strongly preferred injectables to daily oral optio ...

Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to moderate ...

As with other drugs, icatibant can cause side effects, such as dizziness and injection reactions. If icatibant side effects become difficult to tolerate, talk with your doctor or pharmacist. Icatibant ...

Of particular concern are patients with severe lipoatrophy of the extremities. These individuals or their caregivers may need to search for sites with more subcutaneous fat to avoid injection into the ...

– Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office – – This approval is backed by a decade of proven ...

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...